Related Experiment Video
Updated: May 25, 2026
12:03
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*.
D H Thamm1, D A Kamstock, C R Sharp
1Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
Veterinary and Comparative Oncology
|January 13, 2012
Summary
Serum thymidine kinase 1 (TK1) activity is elevated in dogs with hemangiosarcoma (HSA) and splenic masses. This biomarker may help differentiate cancerous splenic masses from benign conditions in dogs with hemoabdomen.
Area of Science:
- Veterinary Medicine
- Oncology
- Biochemistry
Background:
- Thymidine kinase 1 (TK1) is a soluble enzyme linked to DNA synthesis.
- Elevated TK1 activity is observed in various cancers due to increased cell proliferation.
- Hemangiosarcoma (HSA) is a common and aggressive splenic tumor in dogs, often presenting with hemoabdomen.
Purpose of the Study:
- To assess serum TK1 activity as a diagnostic biomarker in dogs with hemoabdomen and splenic masses.
- To differentiate between hemangiosarcoma (HSA) and benign splenic disease in affected dogs.
- To evaluate the diagnostic performance of TK1 activity in distinguishing HSA from normal controls and benign conditions.
Main Methods:
- Prospective study involving 62 dogs with hemoabdomen and splenic masses, plus 15 healthy controls.
- Serum TK1 activity was measured using an enzyme-linked immunosorbent assay (ELISA) with azidothymidine as the substrate.
- Statistical analysis was performed to compare TK1 levels between groups and calculate diagnostic accuracy metrics.
Main Results:
- Serum TK1 activity was significantly higher in dogs with HSA compared to normal dogs (17.0 ± 5.0 U/L vs. 2.01 ± 0.6 U/L).
- TK1 activity was not significantly different between dogs with HSA and those with benign splenic disease (17.0 ± 5.0 U/L vs. 10.0 ± 3.3 U/L).
- A TK1 cut-off of 6.55 U/L showed a sensitivity of 0.52 and specificity of 0.93 for distinguishing HSA from normal dogs. Combined interval thresholds improved diagnostic utility.
Conclusions:
- Serum TK1 activity may serve as a useful biomarker to help discriminate between hemangiosarcoma and benign splenic disease in dogs presenting with hemoabdomen.
- Further refinement of TK1 activity thresholds could enhance its diagnostic value for splenic masses in dogs.
- This non-invasive biomarker evaluation offers potential for improved diagnostic strategies in canine splenic disease.
